Public Companies
“Multi-Bagger” Portfolio Outperformed The S&P 500 Last Week
Cannabis, psychedelic and plant-based food stocks were extremely oversold in 2022 but many of them could possibly bounce back with major returns – dare…
Cannabis, psychedelic and plant-based food stocks were extremely oversold in 2022 but many of them could possibly bounce back with major returns – dare I say “multi-bagger” returns – in 2023. As such, I have created a basket of 12 mostly microcap stocks with market capitalizations between $100M and $399M (average of $189M), aptly named the “Multi-bagger” Portfolio.
An original article by Lorimer Wilson, Managing Editor of munKNEE.com – Your KEY To Making Money!
Below are how the various categories and their constituents have performed year-to-date and performed last week.
- American Cannabis MSO constituents:
- Acreage (ACRDF/ACRHF): +60.8% YTD, +14.2% last week;
- Ascend (AAWH): +6.2% YTD, +6.2% last week;
- Ayr (AYRWF): +5.0% YTD, -1.6% last week;
- Columbia Care (CCHWF): -2.7% YTD, No Change last week;
- Jushi (JUSHF): -20.3% YTD, -9.2% last week; and
- Planet 13 (PLNHF): +30.4% YTD, No Change last week.
- +15.4% YTD; Last week: +3.7%
- Read: 12 Largest American Cannabis MSO Stocks Up 7% Last Week
- Canadian Cannabis LP constituents:
- Aurora (ACB): +19.1% YTD, +3.9% last week; and
- Organigram (OGI): +16.7% YTD, -1.1% last week.
- +18.0% YTD; Last week: +1.5%
- Read: 5 Largest Canadian Cannabis Stocks Flat This Week
- Psychedelic Drug Stock constituents:
- Cybin (CYBN): + 51.7% YTD, +10.0% last week;,
- Mind Medicine (MNMD): +58.7% YTD, +0.6% last week; and
- Seelos Therapeutics (SEEL): +29.2% YTD, +3.7% last week.
- +51.9% YTD; Last week: +1.9%
- Read: 6 Largest Psychedelic Stocks Down 3% This Week
- Plant-Based Food Stock constituent:
- Tattooed Chef (TTCF): +33.1% YTD, +4.4% last week.
- +33.1% YTD; Last week: +4.4%
- Tattooed Chef (TTCF): +33.1% YTD, +4.4% last week.
Grand Total: +27.2% YTD; Last week: +2.9%
The portfolio is outperforming the S&P 500 which was only +1.6% last week and is only +7.7% YTD. It is also outperforming our “Rags-to-Riches” Portfolio which, while +3.0% last week, is only +15.2% YTD.
psychedelic cybin mind medicine seelos therapeutics seelos-
Psilocybin7 days ago
The Psychedelic Scene in Oaxaca, Mexico
-
Law & Regulation1 week ago
GH Research advances depression therapies, burns cash
-
Psychedelics1 week ago
MindBio Therapeutics Scientists Present Landmark Women’s Health Trials, Company to Release Phase 2A Depression Trial Secondary Data This Month
-
Law & Regulation4 days ago
FDA to weigh safety, impact of MDMA therapy for PTSD at June meeting
-
Psychedelics5 days ago
Numinus Wellness Focused on Boosting Profitability and Expanding Community Support
-
Psychedelics1 week ago
PharmAla Launches Prescriber’s Portal for Medical Professionals Focused on MDMA Therapy
-
Psychedelics5 days ago
MindMed Reports First Quarter 2024 Financial Results and Business Updates
-
Psychedelics6 days ago
Oprah Daily’s Comprehensive Guide to Psychedelics: A Milestone for Industry Acceptance